PHC 102

Drug Profile

PHC 102

Alternative Names: 99mTc-CAIX; PHC102

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Philochem
  • Class Radiopharmaceutical diagnostics; Small molecules; Technetium compounds
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Renal cell carcinoma
  • Preclinical Prostate cancer

Most Recent Events

  • 26 Feb 2018 Phase-I clinical trials in Renal cell carcinoma (Diagnosis) in Switzerland (Parenteral) (Philogen pipeline, February 2018)
  • 27 Feb 2017 Philochem plans a phase I trial for diagnosis of Renal cell carcinoma (Philochem pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top